201 related articles for article (PubMed ID: 36114787)
1. The impairment of induction chemotherapy for stage II nasopharyngeal carcinoma treated with intensity-modulated radiotherapy with or without concurrent chemotherapy: A propensity score-matched analysis.
Lai Y; Wang C; Yang X; He S; Wang Y; Chen Y
Cancer Med; 2023 Feb; 12(3):2970-2978. PubMed ID: 36114787
[TBL] [Abstract][Full Text] [Related]
2. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
[TBL] [Abstract][Full Text] [Related]
3. Concurrent chemoradiotherapy versus radiotherapy alone in older patients with stage II nasopharyngeal carcinoma after intensity-modulated radiotherapy: A propensity score-matched cohort study.
Wang F; Zhou L; Zhang LJ; Xie CB; Liao ZW; Lin XD; Wen YF
Radiother Oncol; 2024 Feb; 191():110081. PubMed ID: 38185256
[TBL] [Abstract][Full Text] [Related]
4. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial.
Yang Z; Cai Z; Cai Q; Hong Y; Zhang C; Huang K; Lin Z; Li M
Cancer Med; 2021 Jun; 10(12):3886-3895. PubMed ID: 33955190
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of induction chemotherapy or adjuvant chemotherapy added to concurrent chemoradiotherapy in T3-4N0-1M0 nasopharyngeal carcinoma: a propensity score-matched analysis.
Zhong Q; Luo D; Li X; Du Q; Liang Q; Liu W; Li J; Zhu X
Cancer Biol Ther; 2023 Dec; 24(1):2274121. PubMed ID: 37965924
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
Li PJ; Mo HY; Luo DH; Hu WH; Jin T
Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
[TBL] [Abstract][Full Text] [Related]
7. Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients: a retrospective controlled study.
Liu L; Fei Z; Chen M; Zhao L; Su H; Gu D; Lin B; Cai X; Lu L; Gao M; Ye X; Jin X; Xie C
Radiat Oncol; 2018 Aug; 13(1):148. PubMed ID: 30103765
[TBL] [Abstract][Full Text] [Related]
8. Comparison of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in Lymph-Node-Stage III nasopharyngeal carcinoma based on propensity score-matching.
Liu ZC; Zeng KH; Gu ZB; Chen RP; Luo YJ; Tang LQ; Zhu KB; Liu Y; Sun XS; Zeng L
Radiother Oncol; 2023 Jan; 178():109421. PubMed ID: 36410548
[TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy followed by intensity-modulated radiotherapy versus concurrent chemoradiotherapy in nasopharyngeal carcinoma: A retrospective analysis.
He Y; Zhao Z; Wang Y; He J; Chai J; Wei Z; Guan H; Wang J; Liu Z; Li R; Mu X; He L; Peng X
Clin Otolaryngol; 2021 Sep; 46(5):976-982. PubMed ID: 33821552
[TBL] [Abstract][Full Text] [Related]
10. Retrospective Analysis of Induction Chemotherapy plus Concurrent Chemoradiotherapy under Intensity-Modulated Radiotherapy Mode for Locally Advanced Nasopharyngeal Carcinoma.
Liao K; Tao HY; Zhan ZJ; Qiu WZ; Zheng RH
Oncol Res Treat; 2021; 44(11):602-612. PubMed ID: 34601467
[TBL] [Abstract][Full Text] [Related]
11. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
Wei Z; Zhang Z; Luo J; Li N; Peng X
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
[TBL] [Abstract][Full Text] [Related]
12. Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis.
Li Y; Tang LQ; Liu LT; Guo SS; Liang YJ; Sun XS; Tang QN; Bei JX; Tan J; Chen S; Ma J; Zhao C; Chen QY; Mai HQ
Cancer Res Treat; 2018 Oct; 50(4):1304-1315. PubMed ID: 29334605
[TBL] [Abstract][Full Text] [Related]
13. MRI-based radiomics to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A multicenter study.
Shen H; Yin J; Niu R; Lian Y; Huang Y; Tu C; Liu D; Wang X; Lan X; Yuan X; Zhang J
Radiother Oncol; 2022 Jun; 171():107-113. PubMed ID: 35461950
[TBL] [Abstract][Full Text] [Related]
14. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study.
Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538
[TBL] [Abstract][Full Text] [Related]
15. Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study.
Liu DH; Zhou XY; Pan YG; Chen S; Ye ZH; Chen GD
Cancer Med; 2020 Feb; 9(4):1287-1297. PubMed ID: 31859464
[TBL] [Abstract][Full Text] [Related]
16. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma.
Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X
Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy and intensity-modulated radiotherapy alone for stage II nasopharyngeal carcinoma.
Chen KH; Zhu XD; Li L; Qu S; Liang ZQ; Liang X; Pan XB; Liang ZG; Jiang YM
Oncotarget; 2016 Oct; 7(42):69041-69050. PubMed ID: 27634892
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study.
Zhang WW; Lin JY; Wang GY; Huang CL; Tang LL; Mao YP; Zhou GQ; Liu LZ; Tian L; Li JB; Ma J; Guo R
Radiother Oncol; 2024 May; 194():110189. PubMed ID: 38432309
[TBL] [Abstract][Full Text] [Related]
19. Nomogram Predicting the Benefits of Adding Concurrent Chemotherapy to Intensity-Modulated Radiotherapy After Induction Chemotherapy in Stages II-IVb Nasopharyngeal Carcinoma.
Liu SL; Sun XS; Lu ZJ; Chen QY; Lin HX; Tang LQ; Bei JX; Guo L; Mai HQ
Front Oncol; 2020; 10():539321. PubMed ID: 33240805
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of induction chemotherapy in lymph node-positive stage III nasopharyngeal carcinoma and identification of beneficiaries based on clinical features: A propensity score matching analysis.
Xu YC; Chen KH; Liang Y; Chen KQ; Liang ZG; Zeng FY; Li L; Qu S; Zhu XD
Oral Oncol; 2023 Nov; 146():106554. PubMed ID: 37633201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]